Nektar Therapeutics Shares Outstanding History (NKTR)
Nektar Therapeutics reported 1.4M shares outstanding at the end of fiscal 2025.
View full Nektar Therapeutics company overviewNektar Therapeutics annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 1.4M | 1.4M | +2250.64% |
| 2024 | 2024-12-31 | 60,686.505 | 60,380.161 | +19709.95% |
| 2023 | 2023-12-31 | 306.344 | 4.52 | +1.50% |
| 2022 | 2022-12-31 | 301.823 | 4.949 | +1.67% |
| 2021 | 2021-12-31 | 296.874 | 8.607 | +2.99% |
| 2020 | 2020-12-31 | 288.267 | 5.74 | +2.03% |
| 2019 | 2019-12-31 | 282.527 | 4.762 | +1.71% |
| 2018 | 2018-12-31 | 277.765 | 22.419 | +8.78% |
| 2017 | 2017-12-31 | 255.346 | 10.103 | +4.12% |
| 2016 | 2016-12-31 | 245.243 | 28.689 | +13.25% |
| 2015 | 2015-12-31 | 216.554 | 6.52 | +3.10% |
| 2014 | 2014-12-31 | 210.034 | 23.565 | +12.64% |
| 2013 | 2013-12-31 | 186.469 | 1.977 | +1.07% |
| 2012 | 2012-12-31 | 184.492 | 1.239 | +0.68% |
| 2011 | 2011-12-31 | 183.253 | 31.962 | +21.13% |
| 2010 | 2010-12-31 | 151.291 | — | — |
Nektar Therapeutics quarterly shares outstanding
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 20.4M | 19.5M | +2237.00% |
| Q1 2026 | 2026-03-31 | 20.4M | 7.4M | +56.43% |
| Q4 2025 | 2025-12-31 | 20.4M | 19.5M | +2138.68% |
| Q3 2025 | 2025-09-30 | 1.4M | 1.3M | +2183.03% |
| Q2 2025 | 2025-06-30 | 872,007.64 | 867,798.757 | +20618.27% |
| Q1 2025 | 2025-03-31 | 13.0M | 13.0M | +4432095.39% |
| Q4 2024 | 2024-12-31 | 910,307.3 | 910,000.956 | +297052.46% |
| Q3 2024 | 2024-09-30 | 60,256.581 | 59,951.219 | +19632.82% |
| Q2 2024 | 2024-06-30 | 4,208.883 | 3,904.564 | +1283.05% |
| Q1 2024 | 2024-03-31 | 293.922 | −8.981 | −2.97% |
| Q4 2023 | 2023-12-31 | 306.344 | 4.52 | +1.50% |
| Q3 2023 | 2023-09-30 | 305.362 | 4.509 | +1.50% |
| Q2 2023 | 2023-06-30 | 304.319 | 4.344 | +1.45% |
| Q1 2023 | 2023-03-31 | 302.904 | 4.74 | +1.59% |
| Q4 2022 | 2022-12-31 | 301.823 | 4.949 | +1.67% |
| Q3 2022 | 2022-09-30 | 300.853 | 5.442 | +1.84% |
| Q2 2022 | 2022-06-30 | 299.974 | 5.814 | +1.98% |
| Q1 2022 | 2022-03-31 | 298.164 | 6.377 | +2.19% |
| Q4 2021 | 2021-12-31 | 296.874 | 8.607 | +2.99% |
| Q3 2021 | 2021-09-30 | 295.411 | 8.259 | +2.88% |
| Q2 2021 | 2021-06-30 | 294.161 | 7.944 | +2.78% |
| Q1 2021 | 2021-03-31 | 291.787 | 7.086 | +2.49% |
| Q4 2020 | 2020-12-31 | 288.267 | 5.74 | +2.03% |
| Q3 2020 | 2020-09-30 | 287.151 | 5.775 | +2.05% |
| Q2 2020 | 2020-06-30 | 286.217 | 6.153 | +2.20% |
| Q1 2020 | 2020-03-31 | 284.701 | 5.818 | +2.09% |
| Q4 2019 | 2019-12-31 | 282.527 | 4.762 | +1.71% |
| Q3 2019 | 2019-09-30 | 281.376 | 4.368 | +1.58% |
| Q2 2019 | 2019-06-30 | 280.064 | 4.083 | +1.48% |
| Q1 2019 | 2019-03-31 | 278.882 | 18.966 | +7.30% |
| Q4 2018 | 2018-12-31 | 277.765 | 22.419 | +8.78% |
| Q3 2018 | 2018-09-30 | 277.008 | 25.777 | +10.26% |
| Q2 2018 | 2018-06-30 | 275.98 | 26.498 | +10.62% |
| Q1 2018 | 2018-03-31 | 259.916 | 12.242 | +4.94% |
| Q4 2017 | 2017-12-31 | 255.346 | 10.103 | +4.12% |
| Q3 2017 | 2017-09-30 | 251.231 | 30.664 | +13.90% |
| Q2 2017 | 2017-06-30 | 249.483 | 30.827 | +14.10% |
| Q1 2017 | 2017-03-31 | 247.674 | 29.741 | +13.65% |
| Q4 2016 | 2016-12-31 | 245.243 | 28.689 | +13.25% |
| Q3 2016 | 2016-09-30 | 220.567 | 7.329 | +3.44% |
| Q2 2016 | 2016-06-30 | 218.655 | 7.07 | +3.34% |
| Q1 2016 | 2016-03-31 | 217.933 | 7.523 | +3.58% |
| Q4 2015 | 2015-12-31 | 216.554 | 6.52 | +3.10% |
| Q3 2015 | 2015-09-30 | 213.237 | 7.954 | +3.87% |
| Q2 2015 | 2015-06-30 | 211.585 | 7.842 | +3.85% |
| Q1 2015 | 2015-03-31 | 210.41 | 7.227 | +3.56% |
| Q4 2014 | 2014-12-31 | 210.034 | 23.565 | +12.64% |
| Q3 2014 | 2014-09-30 | 205.283 | 19.621 | +10.57% |
| Q2 2014 | 2014-06-30 | 203.743 | 18.573 | +10.03% |
| Q1 2014 | 2014-03-31 | 203.183 | 18.368 | +9.94% |
| Q4 2013 | 2013-12-31 | 186.469 | 1.977 | +1.07% |
| Q3 2013 | 2013-09-30 | 185.662 | 1.468 | +0.80% |
| Q2 2013 | 2013-06-30 | 185.171 | 1.445 | +0.79% |
| Q1 2013 | 2013-03-31 | 184.815 | 1.393 | +0.76% |
| Q4 2012 | 2012-12-31 | 184.492 | 1.239 | +0.68% |
| Q3 2012 | 2012-09-30 | 184.194 | 1.036 | +0.57% |
| Q2 2012 | 2012-06-30 | 183.725 | 0.76 | +0.42% |
| Q1 2012 | 2012-03-31 | 183.423 | 0.909 | +0.50% |
| Q4 2011 | 2011-12-31 | 183.253 | 31.962 | +21.13% |
| Q3 2011 | 2011-09-30 | 183.159 | — | — |
| Q2 2011 | 2011-06-30 | 182.965 | — | — |
| Q1 2011 | 2011-03-31 | 182.514 | — | — |
| Q4 2010 | 2010-12-31 | 151.291 | — | — |
Nektar Therapeutics shares outstanding trends
Over the last five reported fiscal years, Nektar Therapeutics's shares outstanding moved from 288.267 to 1.4M, a change of 1.4M. The latest reported quarter, Q2 2026, shows 20.4M.
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when SEC-reported stock-split conversion ratios are available. Values remain as reported when no split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Nektar Therapeutics filings at SEC.gov ↗